Osteosarcoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 90 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Osteosarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H2 2014', provides an overview of the Osteosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Osteosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Osteosarcoma - Overview 8
Pipeline Products for Osteosarcoma - Comparative Analysis 9
Osteosarcoma - Therapeutics under Development by Companies 10
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Osteosarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Osteosarcoma - Products under Development by Companies 14
Osteosarcoma - Products under Investigation by Universities/Institutes 15
Osteosarcoma - Companies Involved in Therapeutics Development 16
Advaxis, Inc. 16
Bellicum Pharmaceuticals, Inc. 17
Eleison Pharmaceuticals, Inc. 18
Exelixis, Inc. 19
GlaxoSmithKline plc 20
Novartis AG 21
Sutro Biopharma, Inc. 22
Osteosarcoma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ADXS-HER2 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
alendronate sodium + HPMA + TNP-470 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cabozantinib s-malate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
celyvir - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
cisplatin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, and NY-ESO-1 for Oncology - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
everolimus - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LLL-12 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MBC-11 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pazopanib hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Vaccine for Osteosarcoma - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Osteosarcoma - Recent Pipeline Updates 65
Osteosarcoma - Dormant Projects 84
Osteosarcoma - Discontinued Products 85
Osteosarcoma - Product Development Milestones 86
Featured News & Press Releases 86
May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma 86
Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 86
Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Tables
Number of Products under Development for Osteosarcoma, H2 2014 8
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Osteosarcoma - Pipeline by Advaxis, Inc., H2 2014 16
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 17
Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H2 2014 18
Osteosarcoma - Pipeline by Exelixis, Inc., H2 2014 19
Osteosarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 20
Osteosarcoma - Pipeline by Novartis AG, H2 2014 21
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Assessment by Combination Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Osteosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 65
Osteosarcoma - Dormant Projects, H2 2014 84
Osteosarcoma - Discontinued Products, H2 2014 85